NCT03049189: An ongoing trial by ITM Solucin GmbH
This trial is ongoing. It must report results 4 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03049189 |
|---|---|
| Title | A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 2, 2017 |
| Completion date | Nov. 27, 2024 |
| Required reporting date | Nov. 27, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | July 14, 2025 |
| Days late | None |